CD5L

Across TCGA pan-cancer cohorts, CD5L RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of CD5L’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where CD5L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CD5L is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where CD5L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CD5L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+1.392	<.001	11	view →
LUAD	Male	III,IV	−2.293	<.001	9	view →
LUSC	Female	All	−1.992	<.001	9	view →
LIHC	Male	III,IV	−3.836	<.001	8	view →
CHOL	Female	All	−4.556	<.001	5	view →
KIRP	All	All	+0.654	<.001	4	view →
COAD	Male	All	−0.061	.007	2	view →
BLCA	Female	IV	−0.056	.017	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

CD5L–KIRC

Open the KIRC breakdown →